Phaseline

Companies › BioAtla

BioAtla: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BA3182
Conditionally active bispecific T-cell engager (BiTE) antibody targeting EpCAM and CD3
EPCAM, CD3EPhase 1Advanced AdenocarcinomaSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05808634BA3182Phase 1Advanced AdenocarcinomaOncologySep 2028

From the company's SEC filings

Cash of $2m on 2026-06-30; operating cash outflow about $12m a year; runway about 2 months at that burn, to Aug 2026

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

EPCAM (1) CD3E (1)

Companies with the same targets

Johnson & Johnson (Janssen) Wuhan YZY Biopharma Regeneron Pharmaceuticals Amgen Roche AstraZeneca AcadeMab Biomedical Mirador Therapeutics Tiziana Life Sciences Sanofi

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.